Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case

Koji Ando, Eiji Oki, Masahiko Sugiyama, Yan Zhao, Aya Kojima, Hidetaka Yamamoto, Yoichi Yamashita, Hiroshi Saeki, Akinobu Taketomi, Masaru Morita, Yoshihiro Kakeji, Shunichi Tsujitani, Yoshihiko Maehara

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Extra-gastrointestinal stromal tumors (EGISTs) that do not originate in the digestive tract are rare. We report a case of multiple EGISTs, which was monitored closely by KIT gene mutation analysis and other investigations. The patient was a 52-year-old man in whom multiple tumors in the abdominal cavity were diagnosed as EGISTs. Immunohistochemical analysis revealed positive staining for c-kit; however, no mutations were found in the KIT gene. The tumors decreased in size remarkably following treatment with imatinib mesylate, but after 2 years of this treatment, multiple liver metastases and some regrowth of the abdominal masses were found simultaneously. The liver metastasis and the abdominal masses were excised, and further analysis of the KIT gene revealed the same mutation in exon 11 in the KIT gene in the metastatic tumors. We speculate that the treatment might have triggered development of the imatinib mesylate-resistant clone, which may have existed in the primary lesion as a KIT gene mutant. This report provides valuable insight into the mechanisms of recurrent GISTs after treatment with imatinib mesylate.

Original languageEnglish
Pages (from-to)1290-1293
Number of pages4
JournalSurgery today
Issue number9
Publication statusPublished - Sept 2011

All Science Journal Classification (ASJC) codes

  • Surgery


Dive into the research topics of 'Secondary resistance of extra-gastrointestinal stromal tumors to imatinib mesylate: Report of a case'. Together they form a unique fingerprint.

Cite this